DAFTAR PUSTAKA

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention. JAMA - J Am Med Assoc 2020;323(13):1239–42.
2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet [Internet] 2020;395(10229):1054–62. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30566-3
3. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382(18):1708–20.
4. Wang L, Gao P, Zhang M, Huang Z, Zhang D, Deng Q, et al. Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013. JAMA - J Am Med Assoc 2017;317(24):2515–23.
5. Deng SQ, Peng HJ. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 2020;9(2).
6. Yang JK, Feng Y, Yuan MY, Yuan SY, Fu HJ, Wu BY, et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet Med 2006;23(6):623–8.
7. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc 2020;323(11):1061–9.
8. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: Outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr Clin Res Rev 2020;283–7.
9. Yang J, Zheng Y, Gou X, Pu K, Chen Z. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis [Internet] 2020;94(March):91–5. Available from: https://pubmed.ncbi.nlm.nih.gov/32173574/

10. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC Wkly 2020;2(x):1–10.
11. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA - J Am Med Assoc 2020;323(18):1775–6.
12. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series. N Engl J Med 2020;382(21):2012–22.
13. COVID-19 Surveillance Group. Characteristics of COVID-19 patients dying in Italy Report based on available data on March 20 th , 2020. COVID-19 Surveill Gr 2020;4–8.
14. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. J Community Empower Heal 2020;3(2):77.
15. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J Am Med Assoc 2020;324(8):782–93.
16. Hussain A, Bhowmik B, Cristina N. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information. Diabetes Res Clin Pract 2020;(January).
17. Jeong I, Ho K, Kyu M. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . 2020;(January).
18. PERKENI. Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2019. Perkumpulan Endokrinol Indones 2019;1–117.
19. Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR, Aguilar RB. The time

is right for a new classification system for diabetes: Rationale and implications of the β-cell-centric classification schema. Diabetes Care 2016;39(2):179–86.

20. Burhan E, Isbaniah F, Susanto AD, Aditama TY, Soedarsono, Sartono TR, et al. Pneumonia Covid-19 Diagnosis & Penatalaksanaan Di Indonesia. 2020.
21. Mori H, Okubo M, Okamura M, Yamanae K, Kado S, Egusa G, et al. Abnormalities of Pulmonary Function in Patients with Non-insulin-Dependent Diabetes Mellitus. Intern Med 1992;31(2):189–93.
22. Boulbou MS, Gourgoulianis KI, Petinaki EA, Klisiaris VK, Maniatis AN, Molyvdas PA. Pulmonary function and circulating adhesion molecules in patients with diabetes mellitus. Can Respir J 2003;10(5):259–64.
23. Vracko R, Thorning D, Huang TW. Basal lamina of alveolar epithelium and capillaries: Quantitative changes with aging and in diabetes mellitus. Am Rev Respir Dis 1979;120(5):973–83.
24. Mancini M, Filippelli M, Seghieri G, Iandelli I, Innocenti F, Duranti R, et al. Respiratory muscle function and hypoxic ventilator control in patients with type I diabetes. Chest [Internet] 1999;115(6):1553–62. Available from: http://dx.doi.org/10.1378/chest.115.6.1553
25. Luepker R. Epidemiology of atherosclerotic diseases in population groups. In: Primer in preventive cardiology. Dallas: American Heart Association; 1994. page 1–11.
26. Fuso L, Pitocco D, Antonelli-Incalzi R. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. Diabetes Metab Res Rev 2019;35(6).
27. Kulcsar KA, Coleman CM, Beck SE, Frieman MB. Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection. JCI Insight 2019;4(20).
28. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, et al. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002;106(2):246–53.

29. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020;181(2):271-280.e8.

30. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005;11(8):875–9.

31. Gemmati D, Bramanti B, Serino ML, Secchiero P. COVID 19 and individual genetic ACE. Int J Mol Sci. 2020;21(3474):1–23.

32. Leng J, Goldstein DR. Impact of aging on viral infections. Microbes Infect. 2010;12(14–15):1120–4.

33. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22.

34. Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-Specific Antibodies among Adults in Los Angeles County, California, on April 10-11, 2020. JAMA - J Am Med Assoc. 2020;323(23):2425–7.

35. Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–100.

36. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–60.

37. Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5: 431–37.

38. Kario K, Morisawa Y, Sukonthasan A, Turana Y, Chia C, et al. Covid-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network, The journal of clinical hypertension. 2020 vol 22, no.27.pp. 1109-19

39. Schiffrin E, Flack JM, Ito S, Muntner P. Webb, "Hypertension and Covid-19". American Journal of hypertension. 2020. vol.33.no.5.pp.373-4

40. Caci G, Albini A, Malerba M, Noonan M, Pochetti P, et al. Covid-19 and obesity: Dangerous liaisons. Journal of clinical medicine. 2020. vol.9.no.9.no.2511,pp. 1-12

41. Hussain A, Mahawar K, Xia Z, Elhasani S. Obesity research & clinical practice.2021.vol 15.no 1.pp. 100-5

42. Yu W, Rohli KE, Yang S, Jia P. Impact of obesity on Covid-19 patients. Journal of diabetes and its complications. 2021. vol 35.no 107817.pp.1-14

43. Surendra H, Elyazar IR, Djaafara BA, Ekawati LL, Saraswati K, Adrian V, et al. Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study. Lancet Reg Heal - West Pacific [Internet] 2021;9:100108. Available from: https://doi.org/10.1016/j.lanwpc.2021.100108

44. Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients with Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care 2020;43(7):1382–91.

45. McGurnaghan SJ, Weir A, Bishop J, Kennedy S, Blackbourn LAK, McAllister DA, et al. Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland Stuart. 2020;(January):19–21.

46. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res Care 2020;8(1):1–9.

47. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol 2020;14(4):813–21.

48. Sarigumba MB, Aragon J, Kanapi MP. Baseline glycemic status and outcome of persons with type 2 diabetes with COVID-19 infections: A single-center retrospective study. J ASEAN Fed Endocr Soc 2021;36(1):45–9.

49. Schlesinger S, Neuenschwander M, Lang A, Pafili K, Kuss O, Herder C, et al. Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis. Diabetologia 2021;64(7):1480–91.

50. Pasquel FJ, Messler J, Booth R, Kubacka B, Mumpower A, Umpierrez G, et al. Characteristics of and Mortality Associated with Diabetic Ketoacidosis among US Patients Hospitalized with or without COVID-19. JAMA Netw Open 2021;4(3):28–31.